GlassScriptPhysician profile
Alice Pharies Carter
NPI 1407490097
$4,292.21
in general payments reported to CMS, 2019-2025
29 companies · $2,322 in 2025
The $2,322 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $235 · 2023: $210 · 2024: $1,346 · 2025: $2,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,860 · Education: $17.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.35 |
| Education | $17.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $921.95 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $438.13 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $346.04 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $315.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $267.86 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $264.56 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $215.89 | 2023-2025 | Dupixent |
| Genzyme Corporation | $209.39 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.20 | 2024-2025 | Xifaxan, Trulance, Plenvu |
| Csl Behring | $151.54 | 2021-2023 | Kcentra |
| Janssen Pharmaceuticals, INC | $142.51 | 2021-2023 | Xarelto |
| Boston Scientific Corporation | $118.55 | 2022 | |
| Ardelyx, INC. | $96.75 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $75.59 | 2025 | Voquezna |
| Pfizer INC. | $71.14 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $59.35 | 2025 | |
| Merck Sharp & Dohme LLC | $54.02 | 2024 | Dificid, Zerbaxa |
| Astrazeneca Pharmaceuticals LP | $52.67 | 2022-2023 | Lokelma |
| Alnylam Pharmaceuticals INC. | $51.97 | 2024-2025 | Givlaari |
| Evoke Pharma, INC. | $41.63 | 2024 | |
| Aimmune Therapeutics, INC. | $40.40 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $38.41 | 2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $37.80 | 2024 | Iqirvo |
| Enterra Medical, INC. | $23.82 | 2024 | |
| Btg International INC. | $18.65 | 2021 | |
| Celltrion USA INC. | $17.95 | 2024 | Zymfentra |
| Novo Nordisk INC | $17.00 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $15.57 | 2021 | |
| Celgene Corporation | $13.86 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.